177Lu-PSMA-617联合或不联合ARPI治疗mCRPC的疗效分析
该回顾性研究分析256例既往ARPI进展后接受177Lu-PSMA-617的mCRPC患者,其中41.4%同期使用ARPI。同期ARPI组基线PSA更低、骨和内脏转移率更低、完成6周期比例更高,PSA50应答率相似,中位OS在单因素分析中更长,但多因素校正后无显著差异。
要点
- 同期ARPI组基线预后因素更好,完成6周期比例更高。
- 两组PSA50应答率相似(49.1% vs 47.3%)。
- 多因素校正后同期ARPI与OS无显著关联。
核心结论
- 在既往ARPI进展的mCRPC患者中,继续联用ARPI并未改善PSA50应答率或OS(校正后)。
研究设计与样本
- 单中心回顾性分析Mayo Clinic Rochester放射性药物数据库,纳入2022年3月至2023年3月启动177Lu-PSMA-617且既往ARPI进展的mCRPC患者256例。
主要发现
- 106例(41.4%)同期接受ARPI(阿比特龙、恩扎卢胺、阿帕他胺或达罗他胺)。
- 同期ARPI组基线PSA更低(3.4 vs 29.7 ng/ml,p < 0.001),骨转移率更低(77.4% vs 87.4%,p = 0.035),内脏转移率更低(18.9% vs 34%,p = 0.008)。
- 同期ARPI组完成全部6周期比例更高(63.2% vs 48.7%,p < 0.001)。
- PSA50应答率相似(49.1% vs 47.3%,p = 0.786)。
- 中位OS同期ARPI组未达到 vs 15.3个月(p < 0.001),但多因素分析无显著差异(HR = 1.03,95%CI 0.68-1.55,p = 0.891)。
临床怎么用
- 对于既往ARPI进展的mCRPC患者,启动177Lu-PSMA-617时是否继续ARPI应个体化,不应期望通过联用ARPI改善PSA50应答或OS。
局限性
- 单中心回顾性设计。
- 缺乏标准化的影像学应答评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Large clinical trials, including VISION, have established the safety of combining [177Lu]Lu-PSMA-617 with an androgen receptor pathway inhibitor (ARPI). Most patients receiving [177Lu]Lu-PSMA-617 in the real-world setting have already progressed on an ARPI. This study aimed to assess the efficacy of [177Lu]Lu-PSMA-617 in patients with and without the concurrent use of an ARPI. METHODS: We analyzed data from the Mayo Clinic Rochester radiopharmaceutical database, focusing on patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after prior exposure to an ARPI and started treatment with [177Lu]Lu-PSMA-617 between March 2022 and March 2023. Patients receiving concurrent ARPIs (abiraterone, enzalutamide, apalutamide, or darolutamide) were identified. Baseline characteristics were compared using Mann-Whitney U test and chi-square test. Outcomes of interest included prostate-specific antigen (PSA) 50 response, median number of cycles, and overall survival (OS) from the start of [177Lu]Lu-PSMA-617, analyzed using Kaplan-Meier estimates and multivariate Cox regression. KEY FINDINGS AND LIMITATIONS: Among 256 patients, 106 (41.4%) received an ARPI with [177Lu]Lu-PSMA-617. Those receiving an ARPI had lower baseline PSA levels (3.4 vs 29.7 ng/ml, p < 0.001) and lower rates of bone (77.4% vs 87.4%, p = 0.035) and visceral (18.9% vs 34%, p = 0.008) metastases. While patients on ARPIs were more likely to complete all six cycles of [177Lu]Lu-PSMA-617 (63.2% vs 48.7%, p < 0.001), PSA50 response rates were similar (49.1% vs 47.3%, p = 0.786). Median OS was longer with concurrent ARPI use (not reached vs 15.3 mo, p < 0.001), but this difference was not significant on a multivariate analysis (hazard ratio = 1.03 [95% confidence interval: 0.68-1.55], p = 0.891) after accounting for baseline differences in other prognostic variables. Limitations include its single-center, retrospective design and a lack of standardized radiographic response assessment. CONCLUSIONS AND CLINICAL IMPLICATIONS: Among men with mCRPC previously exposed to an ARPI, continuation of the ARPI with [177Lu]Lu-PSMA-617 did not improve PSA50 response rates or OS after adjusting for cohort imbalances in known prognostic factors. Further post hoc analyses using large clinical trial data are needed.
引用
- Muniz M, Sartor O, Orme JJ, et al. Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2025. PMID: 40752988. doi:10.1016/j.euo.2025.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。